Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Res. 2003 Jun 1;63(11):2723-7.

Magnetic resonance molecular imaging of the HER-2/neu receptor.

Author information

1
Departments of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. dmitri@mri.jhu.edu

Abstract

The HER-2/neu receptor is a member of the epidermal growth factor family and is amplified in multiple cancers. It is under intense investigation both as a prognostic marker and for therapy, using monoclonal antibodies targeted against the receptor. We have developed a novel two-component gadolinium-based MR contrast agent to image the HER-2/neu receptor. Positive T1 contrast in MR images was generated by the specific binding of avidin-gadolinium complexes to tumor cells prelabeled with a biotinylated anti-HER-2/neu antibody. Significant intensity enhancement was observed in HER-2/neu-expressing cell lines and in vivo in a breast cancer model. Potential applications of this approach may include determination of the HER-2/neu status for prognosis and for selecting tumors for monoclonal antibody therapy.

PMID:
12782573
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center